Praxis Precision Medicines (PRAX) Competitors $53.85 -1.09 (-1.98%) Closing price 04:00 PM EasternExtended Trading$53.86 +0.00 (+0.01%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRAX vs. RARE, AAPG, MRUS, ACLX, SWTX, RNA, ACAD, SRRK, VKTX, and PTGXShould you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include Ultragenyx Pharmaceutical (RARE), Ascentage Pharma Group International (AAPG), Merus (MRUS), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), Avidity Biosciences (RNA), ACADIA Pharmaceuticals (ACAD), Scholar Rock (SRRK), Viking Therapeutics (VKTX), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Praxis Precision Medicines vs. Its Competitors Ultragenyx Pharmaceutical Ascentage Pharma Group International Merus Arcellx SpringWorks Therapeutics Avidity Biosciences ACADIA Pharmaceuticals Scholar Rock Viking Therapeutics Protagonist Therapeutics Praxis Precision Medicines (NASDAQ:PRAX) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability. Do institutionals and insiders have more ownership in PRAX or RARE? 67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 2.7% of Praxis Precision Medicines shares are owned by insiders. Comparatively, 5.5% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media refer more to PRAX or RARE? In the previous week, Ultragenyx Pharmaceutical had 41 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 50 mentions for Ultragenyx Pharmaceutical and 9 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.80 beat Ultragenyx Pharmaceutical's score of 0.00 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ultragenyx Pharmaceutical 8 Very Positive mention(s) 5 Positive mention(s) 12 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral Is PRAX or RARE more profitable? Ultragenyx Pharmaceutical has a net margin of -93.04% compared to Praxis Precision Medicines' net margin of -2,137.48%. Praxis Precision Medicines' return on equity of -50.42% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines-2,137.48% -50.42% -46.74% Ultragenyx Pharmaceutical -93.04%-186.49%-36.81% Do analysts prefer PRAX or RARE? Praxis Precision Medicines currently has a consensus target price of $94.11, suggesting a potential upside of 74.77%. Ultragenyx Pharmaceutical has a consensus target price of $83.64, suggesting a potential upside of 217.91%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Praxis Precision Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Praxis Precision Medicines 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93 Which has more risk & volatility, PRAX or RARE? Praxis Precision Medicines has a beta of 2.6, indicating that its stock price is 160% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Which has stronger earnings & valuation, PRAX or RARE? Praxis Precision Medicines has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPraxis Precision Medicines$8.55M128.30-$182.82M-$10.72-5.02Ultragenyx Pharmaceutical$560.23M4.44-$569.18M-$5.88-4.47 SummaryUltragenyx Pharmaceutical beats Praxis Precision Medicines on 10 of the 15 factors compared between the two stocks. Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRAX vs. The Competition Export to ExcelMetricPraxis Precision MedicinesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.12B$2.96B$5.54B$9.41BDividend YieldN/A2.46%3.75%4.03%P/E RatioN/A8.2821.0120.09Price / Sales128.30303.17433.8199.01Price / CashN/A42.5936.1658.27Price / Book2.257.678.125.65Net Income-$182.82M-$55.28M$3.25B$257.91M7 Day Performance6.55%2.50%0.97%2.09%1 Month Performance25.32%11.70%7.36%11.13%1 Year Performance-0.41%4.89%31.31%18.40% Praxis Precision Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRAXPraxis Precision Medicines2.4592 of 5 stars$53.85-2.0%$94.11+74.8%-0.3%$1.12B$8.55M0.00110News CoverageAnalyst ForecastAnalyst RevisionRAREUltragenyx Pharmaceutical4.3814 of 5 stars$39.61-0.8%$87.00+119.6%-37.5%$3.77B$560.23M-6.741,294Trending NewsAnalyst RevisionGap DownAAPGAscentage Pharma Group InternationalN/A$42.04-1.9%N/AN/A$3.73B$134.35M0.00600Lockup ExpirationMRUSMerus1.9328 of 5 stars$52.58-2.3%$84.64+61.0%+8.6%$3.73B$36.13M-12.8937News CoverageInsider TradeACLXArcellx2.5337 of 5 stars$65.55-2.4%$111.23+69.7%+8.3%$3.70B$107.94M-21.9280Positive NewsSWTXSpringWorks Therapeutics1.3584 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230News CoveragePositive NewsRNAAvidity Biosciences2.1866 of 5 stars$28.80-1.3%$65.59+127.7%-24.6%$3.52B$10.90M-9.60190ACADACADIA Pharmaceuticals3.9879 of 5 stars$20.88-0.3%$27.88+33.5%+22.9%$3.51B$957.80M15.24510SRRKScholar Rock3.1299 of 5 stars$35.48-1.4%$42.67+20.3%+378.9%$3.42B$33.19M-14.02140Analyst ForecastInsider TradeVKTXViking Therapeutics4.6378 of 5 stars$27.51-2.4%$87.15+216.8%-35.7%$3.17BN/A-23.9220Upcoming EarningsPTGXProtagonist Therapeutics1.444 of 5 stars$49.87-2.3%$66.10+32.5%+57.1%$3.16B$434.43M66.49120Positive News Related Companies and Tools Related Companies Ultragenyx Pharmaceutical Competitors Ascentage Pharma Group International Competitors Merus Competitors Arcellx Competitors SpringWorks Therapeutics Competitors Avidity Biosciences Competitors ACADIA Pharmaceuticals Competitors Scholar Rock Competitors Viking Therapeutics Competitors Protagonist Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRAX) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
